Clinical Study Of 2 Doses Of Zenapax On The Prevention Of Acute Rejection After Kidney Transplantation

Objective: To compare the efficacy and safety of Zenapax in preventing renal allograft rejection. Method: 20 cases of renal transplant recipients were divided into 2 groups: Zenapax group(n10), compare group (n=10). All patients received the same immunosuppressive drug regimen. Incidence of rejection episodes, dosage of Neoral and Pred, Concentration of CsA, counts of CD3 cells and CD25, renal function were compared between 2 groups. Results: 1. There were no first ose reactions after Zenapax therapy or other subsequent side effects. None of the patients experienced opportunistic infections or malignancies. 2. Whereas only one of the Zenapax treated recipients had arejection episode, 4 of the controls had a rejection episode. 3. There were no significant changes in the dosage of Neoral or Pred. No changes Concentration of CsA. 4. There were no changes in the percentage or absolute counts of CD3 cells or T-cell subsets after Zenapax therapy. 5. Abnormal liver function occurred in I cases in Zenapax group and compare group respectively. Conclusion: 1. The use of 2 doses of Zenapax is effective in renal graft recipients. 2.Therapy with Zenapax was not associated with significant influences to renal function. 3. The use of 2 doses of Zenapax is simple and convenient. 4. Therapy with Zenapax was found to be generally free of adverse effects. 5.Zenapax therapy did not have an effect on the absolute number of CD3 postive cells, blockade of 1L2-R is likely to be the mechanisms of action of Zenapax.